{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:52:58Z","timestamp":1790941978156,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T00:00:00Z","timestamp":1246492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow\u2010up are lacking.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To present long\u2010terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8\u2010year study. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Of the 108 patients, 24% had a sustained symptomatic response. In the remaining patients, loss of symptomatic response with the initial dose was noted within 3\u201060 months. In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment. Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotide LAR, and no additional treatment was required. No significant adverse effects were noted.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Octreotide LAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04083.x","type":"journal-article","created":{"date-parts":[[2009,7,2]],"date-time":"2009-07-02T05:39:06Z","timestamp":1246513146000},"page":"733-740","source":"Crossref","is-referenced-by-count":58,"title":["Long\u2010term results of patients with malignant carcinoid syndrome receiving octreotide LAR"],"prefix":"10.1111","volume":"30","author":[{"given":"C.","family":"TOUMPANAKIS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"GARLAND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"MARELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"SRIRAJASKANTHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"SOH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"DAVIES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"BUSCOMBE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"CAPLIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"e_1_2_6_4_2","first-page":"354","volume-title":"A Century of Advances in Neuroendocrine Tumour Biology and Treatment","author":"Kvols LK","year":"2007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1027392228418"},{"issue":"11","key":"e_1_2_6_6_2","first-page":"1","article-title":"The history of somatostatin analogs","volume":"28","author":"Pless J","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh216"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.3.430"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2005.02.012"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.600"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01420.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0452-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/jsre.2000.5988","article-title":"Radiofrequency ablation treatment of refractory carcinoid hepatic metastases","volume":"85","author":"Wessels FJ","year":"2001","journal-title":"J Surg Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00738.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869309083916"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.12.008"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2007.01.002"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.7.531"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510107"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000111034"},{"key":"e_1_2_6_22_2","first-page":"1111","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors","volume":"116","author":"Perry LJ","year":"1994","journal-title":"Surgery"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.066"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000111037"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0017"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.07.025"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000162876"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04083.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04083.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:13:52Z","timestamp":1697228032000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04083.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,3]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04083.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04083.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,3]]}}}